nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A3—Melphalan—peripheral nervous system neoplasm	0.279	0.519	CbGbCtD
Amphetamine—L-Phenylalanine—Melphalan—peripheral nervous system neoplasm	0.245	1	CrCrCtD
Amphetamine—CYP2A6—Tretinoin—peripheral nervous system neoplasm	0.0848	0.158	CbGbCtD
Amphetamine—SLC22A5—Dactinomycin—peripheral nervous system neoplasm	0.0831	0.155	CbGbCtD
Amphetamine—SLC22A3—Vincristine—peripheral nervous system neoplasm	0.0825	0.154	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00765	0.0143	CbGbCtD
Amphetamine—CARTPT—nerve—peripheral nervous system neoplasm	0.00758	0.172	CbGeAlD
Amphetamine—CARTPT—brainstem—peripheral nervous system neoplasm	0.00325	0.0739	CbGeAlD
Amphetamine—SLC18A2—ganglion—peripheral nervous system neoplasm	0.00254	0.0578	CbGeAlD
Amphetamine—SLC22A3—Abacavir transmembrane transport—ABCB1—peripheral nervous system neoplasm	0.00239	0.063	CbGpPWpGaD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—PINK1—peripheral nervous system neoplasm	0.00203	0.0536	CbGpPWpGaD
Amphetamine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00195	0.0443	CbGeAlD
Amphetamine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.00192	0.0437	CbGeAlD
Amphetamine—SLC22A3—tongue—peripheral nervous system neoplasm	0.00179	0.0407	CbGeAlD
Amphetamine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.00176	0.0401	CbGeAlD
Amphetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.00174	0.0458	CbGpPWpGaD
Amphetamine—MAOB—nerve—peripheral nervous system neoplasm	0.0017	0.0386	CbGeAlD
Amphetamine—MAOB—ganglion—peripheral nervous system neoplasm	0.00168	0.0381	CbGeAlD
Amphetamine—MAOB—Dopamine metabolism—TH—peripheral nervous system neoplasm	0.00164	0.0433	CbGpPWpGaD
Amphetamine—CARTPT—cerebellum—peripheral nervous system neoplasm	0.0016	0.0365	CbGeAlD
Amphetamine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00157	0.0357	CbGeAlD
Amphetamine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.00155	0.0353	CbGeAlD
Amphetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.0015	0.0396	CbGpPWpGaD
Amphetamine—SLC22A3—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.0015	0.0396	CbGpPWpGaD
Amphetamine—DRD2—nerve—peripheral nervous system neoplasm	0.00143	0.0325	CbGeAlD
Amphetamine—DRD2—ganglion—peripheral nervous system neoplasm	0.00141	0.0321	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.0014	0.0369	CbGpPWpGaD
Amphetamine—SLC22A3—Abacavir transport and metabolism—ABCB1—peripheral nervous system neoplasm	0.00137	0.0362	CbGpPWpGaD
Amphetamine—SLC6A4—Synaptic Vesicle Pathway—SYP—peripheral nervous system neoplasm	0.00136	0.0358	CbGpPWpGaD
Amphetamine—CARTPT—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.00124	0.0328	CbGpPWpGaD
Amphetamine—L-Phenylalanine—TH—peripheral nervous system neoplasm	0.00123	0.584	CrCbGaD
Amphetamine—SLC18A2—brainstem—peripheral nervous system neoplasm	0.00111	0.0251	CbGeAlD
Amphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00109	0.0289	CbGpPWpGaD
Amphetamine—SLC22A3—trigeminal ganglion—peripheral nervous system neoplasm	0.00089	0.0202	CbGeAlD
Amphetamine—TAAR1—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.000855	0.0225	CbGpPWpGaD
Amphetamine—SLC22A3—parotid gland—peripheral nervous system neoplasm	0.000839	0.0191	CbGeAlD
Amphetamine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.000836	0.019	CbGeAlD
Amphetamine—MAOB—trigeminal ganglion—peripheral nervous system neoplasm	0.000823	0.0187	CbGeAlD
Amphetamine—SLC18A2—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.000823	0.0217	CbGpPWpGaD
Amphetamine—MAOB—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	0.000819	0.0216	CbGpPWpGaD
Amphetamine—MAOB—parotid gland—peripheral nervous system neoplasm	0.000777	0.0176	CbGeAlD
Amphetamine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.000766	0.0174	CbGeAlD
Amphetamine—MAOB—brainstem—peripheral nervous system neoplasm	0.000729	0.0166	CbGeAlD
Amphetamine—Ephedrine—BCHE—peripheral nervous system neoplasm	0.000681	0.322	CrCbGaD
Amphetamine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.000675	0.0153	CbGeAlD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000653	0.0172	CbGpPWpGaD
Amphetamine—SLC22A5—trigeminal ganglion—peripheral nervous system neoplasm	0.000647	0.0147	CbGeAlD
Amphetamine—DRD2—brainstem—peripheral nervous system neoplasm	0.000615	0.014	CbGeAlD
Amphetamine—SLC6A4—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000611	0.0161	CbGpPWpGaD
Amphetamine—SLC22A5—parotid gland—peripheral nervous system neoplasm	0.00061	0.0139	CbGeAlD
Amphetamine—SLC18A2—cerebellum—peripheral nervous system neoplasm	0.000545	0.0124	CbGeAlD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000538	0.0142	CbGpPWpGaD
Amphetamine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00053	0.014	CbGpPWpGaD
Amphetamine—SLC6A2—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000526	0.0139	CbGpPWpGaD
Amphetamine—DRD2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.000524	0.0138	CbGpPWpGaD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.00049	0.0129	CbGpPWpGaD
Amphetamine—CYP2A6—cerebellum—peripheral nervous system neoplasm	0.000487	0.0111	CbGeAlD
Amphetamine—SLC6A3—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	0.000478	0.0126	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TH—peripheral nervous system neoplasm	0.000466	0.0123	CbGpPWpGaD
Amphetamine—TAAR1—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.000443	0.0117	CbGpPWpGaD
Amphetamine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.000412	0.00937	CbGeAlD
Amphetamine—TAAR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000409	0.0108	CbGpPWpGaD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—TH—peripheral nervous system neoplasm	0.000406	0.0107	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000392	0.0104	CbGpPWpGaD
Amphetamine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000369	0.0084	CbGeAlD
Amphetamine—CARTPT—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000365	0.00962	CbGpPWpGaD
Amphetamine—MAOB—cerebellum—peripheral nervous system neoplasm	0.000359	0.00816	CbGeAlD
Amphetamine—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000323	0.0024	CcSEcCtD
Amphetamine—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.00032	0.00237	CcSEcCtD
Amphetamine—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000319	0.00237	CcSEcCtD
Amphetamine—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000318	0.00236	CcSEcCtD
Amphetamine—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000317	0.00235	CcSEcCtD
Amphetamine—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000317	0.00235	CcSEcCtD
Amphetamine—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000316	0.00234	CcSEcCtD
Amphetamine—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000316	0.00234	CcSEcCtD
Amphetamine—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.000314	0.00233	CcSEcCtD
Amphetamine—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000314	0.00233	CcSEcCtD
Amphetamine—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000314	0.00233	CcSEcCtD
Amphetamine—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000314	0.00233	CcSEcCtD
Amphetamine—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000314	0.00233	CcSEcCtD
Amphetamine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.000313	0.00233	CcSEcCtD
Amphetamine—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000313	0.00232	CcSEcCtD
Amphetamine—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000312	0.00231	CcSEcCtD
Amphetamine—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000312	0.00822	CbGpPWpGaD
Amphetamine—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.00031	0.0023	CcSEcCtD
Amphetamine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000308	0.00229	CcSEcCtD
Amphetamine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000307	0.00228	CcSEcCtD
Amphetamine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000307	0.00228	CcSEcCtD
Amphetamine—DRD2—cerebellum—peripheral nervous system neoplasm	0.000303	0.00689	CbGeAlD
Amphetamine—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000301	0.00224	CcSEcCtD
Amphetamine—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000299	0.00222	CcSEcCtD
Amphetamine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000295	0.00219	CcSEcCtD
Amphetamine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000295	0.00219	CcSEcCtD
Amphetamine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000294	0.00218	CcSEcCtD
Amphetamine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000293	0.00217	CcSEcCtD
Amphetamine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000293	0.00217	CcSEcCtD
Amphetamine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.000291	0.00216	CcSEcCtD
Amphetamine—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.00029	0.00216	CcSEcCtD
Amphetamine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000289	0.00215	CcSEcCtD
Amphetamine—Infection—Vincristine—peripheral nervous system neoplasm	0.000288	0.00214	CcSEcCtD
Amphetamine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000288	0.00213	CcSEcCtD
Amphetamine—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000287	0.00213	CcSEcCtD
Amphetamine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000285	0.00212	CcSEcCtD
Amphetamine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000285	0.00212	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000283	0.0021	CcSEcCtD
Amphetamine—SLC22A5—cerebellum—peripheral nervous system neoplasm	0.000282	0.00641	CbGeAlD
Amphetamine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000282	0.00209	CcSEcCtD
Amphetamine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000281	0.00208	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00028	0.00208	CcSEcCtD
Amphetamine—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000277	0.00205	CcSEcCtD
Amphetamine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000274	0.00204	CcSEcCtD
Amphetamine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000274	0.00203	CcSEcCtD
Amphetamine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000273	0.00202	CcSEcCtD
Amphetamine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000273	0.00202	CcSEcCtD
Amphetamine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000272	0.00202	CcSEcCtD
Amphetamine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000272	0.00202	CcSEcCtD
Amphetamine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000269	0.00199	CcSEcCtD
Amphetamine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000269	0.00199	CcSEcCtD
Amphetamine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000268	0.00199	CcSEcCtD
Amphetamine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000267	0.00198	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000266	0.00197	CcSEcCtD
Amphetamine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000265	0.00197	CcSEcCtD
Amphetamine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000265	0.00197	CcSEcCtD
Amphetamine—Affect lability—Epirubicin—peripheral nervous system neoplasm	0.000264	0.00196	CcSEcCtD
Amphetamine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000263	0.00195	CcSEcCtD
Amphetamine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000263	0.00195	CcSEcCtD
Amphetamine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000263	0.00195	CcSEcCtD
Amphetamine—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000262	0.00194	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.00193	CcSEcCtD
Amphetamine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.00193	CcSEcCtD
Amphetamine—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000258	0.00191	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000257	0.00191	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000257	0.00191	CcSEcCtD
Amphetamine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000257	0.00191	CcSEcCtD
Amphetamine—Infection—Cisplatin—peripheral nervous system neoplasm	0.000255	0.00189	CcSEcCtD
Amphetamine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000255	0.00189	CcSEcCtD
Amphetamine—Mood swings—Epirubicin—peripheral nervous system neoplasm	0.000254	0.00189	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.00188	CcSEcCtD
Amphetamine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000253	0.00188	CcSEcCtD
Amphetamine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000253	0.00188	CcSEcCtD
Amphetamine—Rash—Topotecan—peripheral nervous system neoplasm	0.000253	0.00188	CcSEcCtD
Amphetamine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000252	0.00187	CcSEcCtD
Amphetamine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000252	0.00187	CcSEcCtD
Amphetamine—Headache—Topotecan—peripheral nervous system neoplasm	0.000251	0.00186	CcSEcCtD
Amphetamine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000251	0.00186	CcSEcCtD
Amphetamine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000251	0.00186	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000251	0.00186	CcSEcCtD
Amphetamine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000251	0.00186	CcSEcCtD
Amphetamine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00025	0.00186	CcSEcCtD
Amphetamine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00025	0.00186	CcSEcCtD
Amphetamine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.00025	0.00186	CcSEcCtD
Amphetamine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.00025	0.00185	CcSEcCtD
Amphetamine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00025	0.00185	CcSEcCtD
Amphetamine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000249	0.00185	CcSEcCtD
Amphetamine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000249	0.00185	CcSEcCtD
Amphetamine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000249	0.00185	CcSEcCtD
Amphetamine—Constipation—Vincristine—peripheral nervous system neoplasm	0.000248	0.00184	CcSEcCtD
Amphetamine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000248	0.00184	CcSEcCtD
Amphetamine—Rash—Melphalan—peripheral nervous system neoplasm	0.000247	0.00184	CcSEcCtD
Amphetamine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000247	0.00184	CcSEcCtD
Amphetamine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000246	0.00183	CcSEcCtD
Amphetamine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000245	0.00182	CcSEcCtD
Amphetamine—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000245	0.00182	CcSEcCtD
Amphetamine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000245	0.00182	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.00181	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000242	0.00179	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000242	0.00637	CbGpPWpGaD
Amphetamine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000239	0.00178	CcSEcCtD
Amphetamine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000239	0.00178	CcSEcCtD
Amphetamine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000238	0.00177	CcSEcCtD
Amphetamine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000238	0.00177	CcSEcCtD
Amphetamine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000238	0.00177	CcSEcCtD
Amphetamine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000237	0.00176	CcSEcCtD
Amphetamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000236	0.00175	CcSEcCtD
Amphetamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000236	0.00175	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000235	0.00175	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.00175	CcSEcCtD
Amphetamine—Infection—Etoposide—peripheral nervous system neoplasm	0.000234	0.00173	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000233	0.00173	CcSEcCtD
Amphetamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000233	0.00173	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000231	0.0061	CbGpPWpGaD
Amphetamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00023	0.0017	CcSEcCtD
Amphetamine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00023	0.0017	CcSEcCtD
Amphetamine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00023	0.0017	CcSEcCtD
Amphetamine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000229	0.0017	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000227	0.00169	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000227	0.00168	CcSEcCtD
Amphetamine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000224	0.00166	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.00166	CcSEcCtD
Amphetamine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000223	0.00166	CcSEcCtD
Amphetamine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000222	0.00165	CcSEcCtD
Amphetamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000222	0.00165	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000222	0.00165	CcSEcCtD
Amphetamine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.0016	CcSEcCtD
Amphetamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000214	0.00159	CcSEcCtD
Amphetamine—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00157	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00021	0.00554	CbGpPWpGaD
Amphetamine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.00021	0.00156	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00021	0.00156	CcSEcCtD
Amphetamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000209	0.00155	CcSEcCtD
Amphetamine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000208	0.00155	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000207	0.00153	CcSEcCtD
Amphetamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000206	0.00153	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000205	0.00152	CcSEcCtD
Amphetamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000205	0.00152	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000204	0.00152	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000203	0.00151	CcSEcCtD
Amphetamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000203	0.00151	CcSEcCtD
Amphetamine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000203	0.00151	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000201	0.00531	CbGpPWpGaD
Amphetamine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000201	0.00149	CcSEcCtD
Amphetamine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000201	0.00149	CcSEcCtD
Amphetamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000199	0.00148	CcSEcCtD
Amphetamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000199	0.00147	CcSEcCtD
Amphetamine—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000198	0.00147	CcSEcCtD
Amphetamine—Selegiline—ABCB1—peripheral nervous system neoplasm	0.000197	0.0934	CrCbGaD
Amphetamine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00145	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.00144	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000193	0.00143	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000192	0.00143	CcSEcCtD
Amphetamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000192	0.00143	CcSEcCtD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000192	0.00506	CbGpPWpGaD
Amphetamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000192	0.00142	CcSEcCtD
Amphetamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00019	0.00141	CcSEcCtD
Amphetamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00019	0.00141	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.00141	CcSEcCtD
Amphetamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000189	0.0014	CcSEcCtD
Amphetamine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000189	0.0014	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000188	0.00496	CbGpPWpGaD
Amphetamine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000187	0.00139	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000186	0.00138	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000186	0.00138	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.00138	CcSEcCtD
Amphetamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000185	0.00137	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000184	0.00486	CbGpPWpGaD
Amphetamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000184	0.00137	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000184	0.00485	CbGpPWpGaD
Amphetamine—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.00136	CcSEcCtD
Amphetamine—Rash—Vincristine—peripheral nervous system neoplasm	0.000183	0.00136	CcSEcCtD
Amphetamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000183	0.00136	CcSEcCtD
Amphetamine—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000182	0.00414	CbGeAlD
Amphetamine—Headache—Vincristine—peripheral nervous system neoplasm	0.000182	0.00135	CcSEcCtD
Amphetamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000179	0.00133	CcSEcCtD
Amphetamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000176	0.0013	CcSEcCtD
Amphetamine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000175	0.0013	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000175	0.00462	CbGpPWpGaD
Amphetamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000173	0.00129	CcSEcCtD
Amphetamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000172	0.00128	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000172	0.00454	CbGpPWpGaD
Amphetamine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000169	0.00125	CcSEcCtD
Amphetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	0.000165	0.00436	CbGpPWpGaD
Amphetamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000163	0.00121	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00121	CcSEcCtD
Amphetamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000162	0.0012	CcSEcCtD
Amphetamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000162	0.0012	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000161	0.00119	CcSEcCtD
Amphetamine—TAAR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000161	0.00424	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000159	0.0042	CbGpPWpGaD
Amphetamine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000159	0.00118	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000158	0.00418	CbGpPWpGaD
Amphetamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000157	0.00116	CcSEcCtD
Amphetamine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000156	0.00115	CcSEcCtD
Amphetamine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000153	0.00113	CcSEcCtD
Amphetamine—MAOB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000151	0.00399	CbGpPWpGaD
Amphetamine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00015	0.00111	CcSEcCtD
Amphetamine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000148	0.0011	CcSEcCtD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000148	0.00391	CbGpPWpGaD
Amphetamine—Rash—Etoposide—peripheral nervous system neoplasm	0.000148	0.0011	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000148	0.0011	CcSEcCtD
Amphetamine—Headache—Etoposide—peripheral nervous system neoplasm	0.000147	0.00109	CcSEcCtD
Amphetamine—SLC18A2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000147	0.00388	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000147	0.00388	CbGpPWpGaD
Amphetamine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.00109	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.00108	CcSEcCtD
Amphetamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000143	0.00106	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000142	0.00376	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000141	0.00372	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000141	0.00371	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.00014	0.0037	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00014	0.0037	CbGpPWpGaD
Amphetamine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00014	0.00104	CcSEcCtD
Amphetamine—Nausea—Etoposide—peripheral nervous system neoplasm	0.00014	0.00104	CcSEcCtD
Amphetamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000139	0.00104	CcSEcCtD
Amphetamine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000138	0.00102	CcSEcCtD
Amphetamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.00102	CcSEcCtD
Amphetamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00102	CcSEcCtD
Amphetamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000999	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000981	CcSEcCtD
Amphetamine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000979	CcSEcCtD
Amphetamine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000972	CcSEcCtD
Amphetamine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000961	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000958	CcSEcCtD
Amphetamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000955	CcSEcCtD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000128	0.00338	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000128	0.00338	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000128	0.00337	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000946	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000945	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000941	CcSEcCtD
Amphetamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000933	CcSEcCtD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000125	0.00331	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000125	0.0033	CbGpPWpGaD
Amphetamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000924	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000124	0.00327	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000123	0.00325	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000123	0.00324	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000906	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000121	0.0032	CbGpPWpGaD
Amphetamine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.0009	CcSEcCtD
Amphetamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000885	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000884	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000119	0.00314	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000875	CcSEcCtD
Amphetamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000873	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000117	0.00309	CbGpPWpGaD
Amphetamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00087	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000863	CcSEcCtD
Amphetamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000862	CcSEcCtD
Amphetamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000851	CcSEcCtD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000114	0.00302	CbGpPWpGaD
Amphetamine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000845	CcSEcCtD
Amphetamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000844	CcSEcCtD
Amphetamine—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000837	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000819	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000807	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000805	CcSEcCtD
Amphetamine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000108	0.0008	CcSEcCtD
Amphetamine—SLC6A3—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000108	0.00284	CbGpPWpGaD
Amphetamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000797	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000787	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000782	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000781	CcSEcCtD
Amphetamine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000778	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000774	CcSEcCtD
Amphetamine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000774	CcSEcCtD
Amphetamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000774	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000104	0.00274	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000102	0.0027	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	9.98e-05	0.00263	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.000741	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	9.91e-05	0.00261	CbGpPWpGaD
Amphetamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	9.71e-05	0.000721	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	9.69e-05	0.000719	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	9.64e-05	0.000716	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	9.64e-05	0.000716	CcSEcCtD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	9.59e-05	0.00253	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	9.55e-05	0.00252	CbGpPWpGaD
Amphetamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	9.46e-05	0.000702	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.44e-05	0.00249	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.41e-05	0.00248	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	9.15e-05	0.00241	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.09e-05	0.0024	CbGpPWpGaD
Amphetamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	9.02e-05	0.00067	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000667	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—HGF—peripheral nervous system neoplasm	8.98e-05	0.00237	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	8.84e-05	0.00233	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—BCHE—peripheral nervous system neoplasm	8.76e-05	0.00231	CbGpPWpGaD
Amphetamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.00065	CcSEcCtD
Amphetamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	8.72e-05	0.000647	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	8.68e-05	0.00229	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.65e-05	0.00228	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TH—peripheral nervous system neoplasm	8.6e-05	0.00227	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	8.49e-05	0.00224	CbGpPWpGaD
Amphetamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	8.38e-05	0.000622	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	8.35e-05	0.00062	CcSEcCtD
Amphetamine—Rash—Epirubicin—peripheral nervous system neoplasm	8.31e-05	0.000617	CcSEcCtD
Amphetamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	8.31e-05	0.000617	CcSEcCtD
Amphetamine—Headache—Epirubicin—peripheral nervous system neoplasm	8.26e-05	0.000613	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.25e-05	0.00218	CbGpPWpGaD
Amphetamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	8.07e-05	0.000599	CcSEcCtD
Amphetamine—Nausea—Epirubicin—peripheral nervous system neoplasm	7.83e-05	0.000581	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	7.76e-05	0.000576	CcSEcCtD
Amphetamine—Rash—Doxorubicin—peripheral nervous system neoplasm	7.69e-05	0.000571	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	7.68e-05	0.00057	CcSEcCtD
Amphetamine—DRD2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	7.65e-05	0.00202	CbGpPWpGaD
Amphetamine—Headache—Doxorubicin—peripheral nervous system neoplasm	7.64e-05	0.000567	CcSEcCtD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.54e-05	0.00199	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GNS—peripheral nervous system neoplasm	7.39e-05	0.00195	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.37e-05	0.00194	CbGpPWpGaD
Amphetamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000538	CcSEcCtD
Amphetamine—MAOB—Metabolism—NME1—peripheral nervous system neoplasm	7.09e-05	0.00187	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	7.09e-05	0.00187	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	7.01e-05	0.00185	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—COX2—peripheral nervous system neoplasm	6.82e-05	0.0018	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.52e-05	0.00172	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.52e-05	0.00172	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.5e-05	0.00171	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GNS—peripheral nervous system neoplasm	6.25e-05	0.00165	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	6.2e-05	0.00163	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.07e-05	0.0016	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NME1—peripheral nervous system neoplasm	6e-05	0.00158	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.95e-05	0.00157	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—COX2—peripheral nervous system neoplasm	5.77e-05	0.00152	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.74e-05	0.00151	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	5.63e-05	0.00149	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.58e-05	0.00147	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	5.4e-05	0.00142	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.31e-05	0.0014	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.25e-05	0.00138	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.23e-05	0.00138	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.15e-05	0.00136	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.13e-05	0.00135	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.07e-05	0.00134	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.98e-05	0.00131	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	4.9e-05	0.00129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.88e-05	0.00129	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.7e-05	0.00124	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.5e-05	0.00119	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.49e-05	0.00119	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ENO2—peripheral nervous system neoplasm	4.48e-05	0.00118	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.29e-05	0.00113	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.13e-05	0.00109	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.09e-05	0.00108	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.08e-05	0.00108	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.01e-05	0.00106	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ENO2—peripheral nervous system neoplasm	3.79e-05	0.000999	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—BCHE—peripheral nervous system neoplasm	3.78e-05	0.000998	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.75e-05	0.00099	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.71e-05	0.000979	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	3.67e-05	0.000968	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.62e-05	0.000954	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.61e-05	0.000952	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNS—peripheral nervous system neoplasm	3.6e-05	0.00095	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TH—peripheral nervous system neoplasm	3.56e-05	0.000938	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.55e-05	0.000936	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NME1—peripheral nervous system neoplasm	3.45e-05	0.000911	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.45e-05	0.00091	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—HRAS—peripheral nervous system neoplasm	3.45e-05	0.00091	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.43e-05	0.000904	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.39e-05	0.000894	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—COX2—peripheral nervous system neoplasm	3.32e-05	0.000876	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—BCHE—peripheral nervous system neoplasm	3.2e-05	0.000844	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.05e-05	0.000806	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TH—peripheral nervous system neoplasm	3.01e-05	0.000794	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GNAS—peripheral nervous system neoplasm	2.9e-05	0.000766	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.89e-05	0.000763	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCB1—peripheral nervous system neoplasm	2.85e-05	0.000752	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.79e-05	0.000737	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.77e-05	0.000732	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.68e-05	0.000708	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.68e-05	0.000706	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.52e-05	0.000666	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GNAS—peripheral nervous system neoplasm	2.46e-05	0.000648	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.45e-05	0.000647	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.43e-05	0.000641	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.42e-05	0.000639	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—peripheral nervous system neoplasm	2.41e-05	0.000636	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.24e-05	0.000592	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.23e-05	0.000588	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.2e-05	0.000581	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.19e-05	0.000579	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—peripheral nervous system neoplasm	2.18e-05	0.000575	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.12e-05	0.000559	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	2.06e-05	0.000542	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.04e-05	0.000537	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.02e-05	0.000534	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	2.02e-05	0.000533	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.94e-05	0.000511	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.93e-05	0.000508	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.9e-05	0.000501	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.86e-05	0.000492	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BCHE—peripheral nervous system neoplasm	1.84e-05	0.000486	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.76e-05	0.000464	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TH—peripheral nervous system neoplasm	1.73e-05	0.000457	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.56e-05	0.000411	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.52e-05	0.000401	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.49e-05	0.000393	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNAS—peripheral nervous system neoplasm	1.41e-05	0.000373	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.39e-05	0.000366	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.34e-05	0.000353	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.32e-05	0.000347	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.3e-05	0.000343	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.24e-05	0.000327	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.22e-05	0.000323	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.14e-05	0.0003	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	1.03e-05	0.000273	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.86e-06	0.00026	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	9.72e-06	0.000256	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.04e-06	0.000212	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	7.93e-06	0.000209	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.9e-06	0.000208	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—peripheral nervous system neoplasm	7.84e-06	0.000207	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	7.78e-06	0.000205	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—peripheral nervous system neoplasm	6.63e-06	0.000175	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.25e-06	0.000165	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.88e-06	0.000155	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.72e-06	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.67e-06	0.00015	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.2e-06	0.000137	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.75e-06	0.000125	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.43e-06	0.000117	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—peripheral nervous system neoplasm	3.82e-06	0.000101	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.64e-06	9.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.48e-06	9.17e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.07e-06	8.1e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	2.14e-06	5.65e-05	CbGpPWpGaD
